OTC: LIVG

In
connection with the NuGene Merger Agreement, we entered into a Business Transfer and Indemnity Agreement dated December 29, 2014 (the
“Indemnity Agreement”) with our former Chief Executive Officer and Director, Dena Kurland providing for:

1.
The
transfer of our jewelry business operations existing on the date of the Indemnity Agreement (the “BMI Business”);

2.
The
assumption by Ms. Kurland of all liabilities of our Company and the indemnification by Ms. Kurland holding our Company harmless for
any and all liabilities arising at or before the date of the Indemnity Agreement;

3.
The
payment by NuGene to Ms. Kurland of $350,000 in cash; and

4.
The
surrender by Ms. Kurland of 15,000,000 shares (before giving effect to the Stock Split discussed below) (the “Indemnity Shares”)
of our Company’s common stock representing 95% of the then outstanding common stock (all of which shares have been deemed cancelled
by the Company).

Pursuant
to the terms of the Nugene Merger Agreement, 26,052,760 shares of Company common stock and 1,917,720 Company a newly designated Series
A Preferred Stock were issued to the former NuGene shareholders. The Series A Preferred Stock was: (i) initially convertible into common
stock at a ratio of one to one, (ii) as long as there were a minimum of 900,000 shares of Series A Preferred Stock outstanding, the holders
of the Series A Preferred Stock had the right to elect a majority of the board of directors and (iii) the holders of the Series A Preferred
Stock, generally voting as a class with the holders of common stock, had for each share of Series A Preferred Stock three times the number
of votes permitted to each share of common stock.

On
December 26, 2014, our board of directors approved a 15.04 to one stock split (“Stock Split”) in the form of a stock dividend
to holders of our common stock as of that date. To affect that board action, each recipient of the stock dividend would receive 14.04
additional shares of common stock for every share of common stock held.

On
December 29, 2014, we completed the sale of 2,000,000 shares of our common stock to 18 purchasers (“Stock Placement”) for
proceeds totaling $2,000,000, including (a) $1,625,000 of cash and (b) automatic conversion of promissory notes in the principal amount
of $375,000.

NuGene
was incorporated in California in December 2006 and formed and funded by our founders, Ali Kharazmi and Mohammed Kharazmi, M.D. The initial
focus of NuGene was to develop and market customized skin care products. As part of that focus, NuGene sought to leverage the working
relationships developed by our founders with the plastic surgery community. NuGene directed significant time and resources on developing
anti-aging and scar treatment/reduction products.

4

In
2007 Nugene continued to focus on “age-defying” products utilizing peptide complexes (see further description below)
and nano-encapsulation for absorption into the skin (see additional description below). We introduced a limited product line under
the NuGene name and co-branded the products with an affiliated entity, Genetic Institute of Anti-Aging, Inc. (“GIAA”), which
the Kharazmi owned. We utilized the services of a Korean-based contract manufacturer to supply our products. This product line (the “GIAA
Line”) was based on peptides and did not utilize stem cells. We had very modest sales in 2007, with our sole customer GIAA, a related
party.

In
2008 we stopped production of the GIAA Line, and sales were limited to selling the remaining inventory through medical offices and GIAA.
With the GIAA Line discontinued, we spent the remainder of 2008 considering different formulations and methodologies for improved anti-aging
products.

In
2009 and 2010, we had limited activity and minimal sales. Our sales were mainly overseas and limited to the remaining inventory of the
GIAA Line. We continued to explore how we might advance our formulations and methodologies. We expended funds on research and development,
carried out mainly by scientists engaged by the Company.

In
2011 our founders decided to use adult adipose human stem cells (undifferentiated cells found throughout the body that multiply by cell
division to replenish dying cells and regenerate tissues) as the foundation of the formulation for its products. In 2011 the Company
developed a proprietary process to extract human adult stem cells from fat cells that the Company then used in its customized NuGene
line explicitly made for those client(s). Throughout 2011 we continued to provide autologous, or mature, fat-derived stem cells for use
in clinical procedures utilizing this technology. Through this process, the Company refined its ability to culture adult human stem cells
to render human-conditioned stem cell media at a proprietary concentration, a primary ingredient in the NuGene line of cosmeceuticals.
The Company believes that this proprietary concentration, combined with our unique formulations, will provide NuGene with a significant
competitive advantage.

In
2012 we completed our initial line of cosmeceutical products based on these adipose-derived stem cells. We branded this advanced skincare
line solely under the NuGene name (the “NuGene Line”). We eliminated the unpleasant odor associated with stem cells by adding
a fragrance with a very low incidence of allergic reaction. The packaging of this new product line bears no resemblance to the prior
GIAA Line. We also manufactured the NuGene Line ourselves at a small laboratory facility that we leased from an affiliated entity owned
by one of our founders.

Throughout
2013 we continued to expand the product offerings of the NuGene Line. The Company focused its stem cell work on surgical and orthopedic
regeneration. These services were delivered to one client, which was an affiliated entity. Sales of the NuGene Line were limited as we
were in an initial rollout and branding phase.

During
2014, we focused our efforts on transitioning to a cosmeceutical skincare business for mass distribution. With this transition and expanded
attention to our consumer products, we sought to develop our marketing plan and distribution channels. By the end of 2014, we had wholesalers
distributing products from the NuGene Line to medical offices and medical spas throughout the United States. December 31, 2014, we had
about 50 locations selling our products. In addition to the NuGene Line, we generated revenues from an affiliate, Advanced Surgical Partners
(“ASP”), which is also owned by our CEO and Chairman of the Board, Messrs. Ali and Mohammed Kharazmi, respectively. Revenues
generated from ASP resulted from NuGene providing Plasma Rich Platelet and Stem Cell injections for orthopedic and plastic surgery procedures
to ASP. We provided these products and services to ASP as we transitioned into commercializing our cosmeceutical product lines. We expect
further to minimize these product sales and services to ASP in early 2015.

5

Our
target customers primarily consisted of middle-aged men and women concerned with their aging skin and hair loss. Although our distributors
were primarily west of the Mississippi River, our products were sold throughout the United States.

By
2017, our cosmeceutical skincare business had been discontinued as we could not obtain financing for operations on reasonable terms and
became inactive. Our corporate charter was revoked in Nevada.

On
January 26, 2020, Emergent, LLC (“Emergent”), a Nevada LLC controlled by Milan I Hoffman, was appointed the custodian of
the Company and proceeded to revive the Company’s existence and resolve its outstanding indebtedness. This was completed as to
all indebtedness except for one convertible rate promissory note of $120,000. In March 14th, 2022, Ms. Hoffman sold her Series A Preferred
stock in the Companyto David Stybr. Also in March 2022, David Stybr, CEO and the sole owner of Livento Group, LLC, agreed to contribute
Livento Group, LLC to the Company in exchange for a transfer to him of the 5.000.000 Series C Preferred Stock shares. As a result of
these transactions our current operations are the operations of Livento Group, LLC.

Livento
Group operations started in 2017 as the internal team spearheaded the development of financial management software based on artificial
intelligence for investment entities. This software currently provides several clients with data processing and analytical services in
the investment management sector. Management believes that this segment of our operations will provide meaningful revenue, but we can
give no assurance that this will happen. The product is best described as an automated system that can analyze large quantities of data,
focusing on selected parameters and predicting short-term future behavior within a specific portfolio of selected assets. The software
chooses assets with the highest potential based on a set of specifications and properties, predicting short-term future behavior within
a particular portfolio.

In
2020 the Company acquired land for a residential real estate development project, amounting to 4 million USD, with a completion target
of late 2022. The property is being developed into 16 residential condominiums in a suburb of Prague in the Czech Republic, and all of
the condominium units have signed purchase agreements totaling 12 million. The development cost was approximately 3 million USD. Accordingly,
the gross profits from this project (not counting carrying costs) will be about 5 million USD. The Company had one more real estate project
in the planning phase but planned to sell it and not develop the property further. The Company invested in a residential project total
amount of around 825,000 USD and is currently looking for a buyer. We have had discussions with three potential buyers and expect to
finalize a contract of sale by the end of 2022 but can give no assurances that this will occur or that any sale of this project will
prove profitable. We do not have any further plans to engage in additional real estate development projects.

Present
Operations

The
Company formed BOXO Productions, Inc., a Delaware corporation (“BOXO”), on June 17, 2022 as a wholly owned subsidiary. BOXO
previously operated as a division of Livento that operated since 2020, where we meet with top film and movie producers. BOXO’s
business model is strongly oriented toward the growing demand for content to fill cinemas after COVID19 and the expansion of online content
distributors. BOXO Productions will hold all assets related to Company’s business in movies in the future and currently doesn’t
employ any personnel. In most of its projects, BOXO is not primarily dependent on the movie’s success, as a distributor pays it
before the film is finalized and receives a share of the revenue from cinemas’ box office and home sales. BOXO plans to produce
up to 6 movies and 12 television productions during 2022. BOXO also intends to participate in other films based on management’s
assessment of their potential success in cinemas already in the post-production phase. BOXO will focus on negotiating distribution agreements
that provide for its sharing in the box office sales of these movies. Scripts are chosen by BOXO’s production team, which regularly
receives offers from authors commonly involved in the film industry. BOXO may acquire movie or television rights in various stages of
development. Less frequently, BOXO receives offers for participating in a project’s post-production phase. BOXO finances movies
via internal resources, loans, and investors depending on the project’s state of development and the Company’s cash position.

During
2022 BOXO started production of three movies, Carnival of Killers, Wash Me in the River and Running Wild. These projects received an
initial investment from Livento of USD 400,000 each. Two of these projects, Carnival of Killers and Running Wild are expected to enter
the development stage of production competed in the summer of 2023 and filming and postproduction should end during 4Q 2024. The movie
Wash Me in the River was released in Q4 of 2022.

6

The
team has been involved either as producers, executive producers, or agents over the years on the following movies, which have been aired
both in theaters and streaming services such as Netflix, Prime Video, Paramount, and Disney Plus:

●
The
Misfits; a 2021 Action/Thriller featuring Pierce Brosnan

●
Packaging
of Ironman movie

●
Black
Swan; a 2010 Drama/Thriller featuring Natalie Portman, Mila Kunis, Winona Ryder, and Vincent Cassel

●
Extremely
Wicked, Shockingly Evil and Vile; a 2019 Crime/Drama featuring John Malkovich and Zac Efron

●
Marley
& Me; a 2008 Comedy/Drama featuring Jennifer Aniston and Owen Wilson

●
The
Last Full Measure; a 2019 War/Drama featuring Samuel L. Jackson and Ed Harris

●
Worth;
a 2020 Drama featuring Michael Keaton and Stanley Tucci Jr.

●
American
Traitor: The Trial of Axis Sally; a 2021 Drama that features Al Pacino

●
Best
Sellers; a 2021 Drama/Comedy featuring Michael Caine and Cary Elwes

Currently,
the Company’s primary focus is the activities of BOXO Productions. As previously mentioned, new movies and television productions
are started monthly, with the target being six movies this year. The Company will use the proceeds of the condominium sales to fund the
activity and operations of BOXO.

Per
our plans from last year, the Company does not plan to continue in its real estate activities, and it sold its current projects, and
will not pursue new opportunities in this segment. On May 26, 2023, Boxo Productions, Inc. (“Boxo”) entered into an Assignment
and Purchase Agreement (the “APALO) with Loredo LLC (“LO”) whereunder we acquired interests in total of 45 projects
valued at $22,320,641 from LO for 391,590,193 shares of our common stock. On May 26, 2023, Boxo Technology, Inc. entered into an Assignment
and Purchase Agreement (the “APAWEW”) with West East Wind Limited (“WEWL”) whereunder Boxo Technology, Inc. will
acquire certain rights in 3 gaming apps and transfer to WEWL of its interests in 2 real estate projects Thunder and Geminos (which are
not further pursuing). The assets acquired from WEWL are valued under the APAWEW at $9,929,359.

The
BOXO team is comprised of three consultants that have been in the production business for last 20 – 30 years and has experience
with large productions as the above-mentioned examples. They have together worked on approximately 300 movie projects over the years.
While the terms of our financings vary from movie to movie, we generally form a limited liability company and serve as its managing member.
Our cash investment, in addition to performing the tasks typical of a producer, is generally from $300,000 to $700,000. The rest of the
costs of the movie are provided by investors. We typically retain a 20 % interest in cash flow, although each movie will be done on differing
terms reflecting market conditions and investors’ assessments of the risk involved.

Trends
in the Our Markets

Management
believes that the entertainment industry is experiencing structural changes. COVID19 changed the movie distribution business and offered
new business models and potential growth to participants who provide apps and streaming content directly to consumers through the Internet.
Based on management’s analysis of recent market statistics and trends, we believe these models have become dominant trends in this
market segment.

Management
also believes that these trends will continue and that there is a large market for BOXO’s films and television productions. The
movie production market has expanded significantly in the last two years and is likely to continue growing significantly in the coming
years. Management has observed that online streaming platforms continually require new content, and an increased number of connected
devices will likely result in more customers using these services. In the next few years, many developed and emerging nations will add
new customers to the network.

7

The
Company has internally developed software called “Elisee” that can capture large amounts of data and create predictive behavior
based on client inputs that assist the client in establishing its investment portfolio. Successfully building an equity portfolio is
not simple since one must consider the future of particular industries and the companies within them. Retail investors and Family Offices
lack complex historical data, and this is where Elisee excels. This data has been acquired from Dow Jones and other public sources and
dissected and analyzed. We believe in diversification but place more emphasis on those industries and companies with a more promising
outlook based on guidance from Elisee. Management believes each potential customer’s financial situation and investment needs are
unique. We see the constant shift of the world’s financial markets, real estate prices, CPI data, and effective portfolio management
as the key to success.

Elisee,
our software product, uses algorithms that read market data and neurological network abilities to determine the best path forward and
make ongoing corrections over time. The main idea is based on reducing risk by investing in several assets. Investors should approach
assets individually and carefully assemble them into their portfolios. When creating an optimal portfolio, Elisee constantly measures
two factors. The first factor is a parameter expressing potential profitability, and the second parameter represents risk. It is necessary
to consider the riskiness of the individual assets in the portfolio, their mutual covariance, or their mutual correlation to calculate
the risk of the entire portfolio. Covariance expresses the extent to which two investment instruments move in the same direction at a
specific time.

Our
competitors are other A.I. database and algorithm programming companies delivering services to clients like banks and asset managers.
Elisee is diversification tool.

We
identified this as a unique opportunity to support several companies with different needs and to aid them in their asset selection process.
We developed our system that can read large amounts of data and run portfolio analyses on these assets, providing improved portfolio
management and performance.

The
system’s development commenced in early 2018, and the first version took one year of development and testing with various basic
data sets. Currently, Livento has a team of three analysts who focus on the maintenance and further development of the system. We are
continually developing and improving our software, making it more robust, stable, and capable of supporting an increased number of asset
classes.

Key
summary of points:

●
Elisee
was developed and tested over four years.

●
Elisee
has had a successful and profitable track record for three years.

●
Elisee
can process 1 TB of data in 1 hour.

●
Elisee
uses neurological network algorithms to determine and analyze large data portions.

Marketing
Strategy

Our
marketing strategy comprises the following components; social media (Twitter, LinkedIn, FB, etc.), PR and video communications, and a
personal approach. The strategy differs based on the product offered. They may be described as follows:

Social
media:

We
can rapidly, quickly, and reliantly inform all stakeholders about necessary and relevant news. We use promotional posts to gain company
followers.

PR
and video communications:

A
professional IR agency was hired to write our PR communications, arrange interviews with Management, write articles, and introduce them
via different channels to the media. Video interviews and conference attendance are also planned for more prominent investors’
involvement.

Personal
approach:

Our
software uses a direct and personal approach via different marketing channels, including social networks, industry liaisons, and articles
in specialized magazines.

8

Employees

We
currently have eleven employees and consultants. Three of our employees are specialized in Elisee development, three are engaged in Financial
Management, and two are involved in administrative positions. The remaining employees are engaged in various management positions. We
anticipate hiring additional employees or consultants over the next months to support the growth of BOXO. None of our employees are covered
by a collective bargaining agreement.

Competition

BOXO
competes with other production companies focused on movies and online streaming platforms. Our main market advantage is direct contact
via the producer team to top Hollywood icons, including well-known producers, directors, actors, and distribution companies that pay
BOXO before the film is finalized.

The
competition to our software is other software products performing similar functions. We differentiate ourselves in specializing and providing
a proven track record in several specific market segments, where we can offer predictive behavior of assets with and without our decision-making
process.

In
all aspects of our business, we face competition from companies with more significant resources than we have, but we have gradually and
consistently grown despite this.

We
currently occupy space within serviced office suites in New York City and Prague in the Czech Republic. Since our employees and consultants
work virtually, we believe this arrangement is adequate for us and allows us to operate at a very low cost. In the future, if we require
more office space, we will acquire appropriate quarters within which to operate.